Cullen Frost Bankers Inc. Acquires Shares of 288 ICU Medical, Inc. $ICUI

Cullen Frost Bankers Inc. acquired a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 288 shares of the medical instruments supplier’s stock, valued at approximately $38,000.

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 153 shares in the last quarter. Blue Trust Inc. boosted its holdings in ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock valued at $124,000 after purchasing an additional 141 shares in the last quarter. United Services Automobile Association acquired a new stake in ICU Medical during the first quarter valued at approximately $218,000. Vontobel Holding Ltd. acquired a new stake in ICU Medical during the first quarter valued at approximately $235,000. Finally, Johnson Investment Counsel Inc. boosted its holdings in ICU Medical by 17.7% during the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 256 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $123.48 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The firm has a market cap of $3.05 billion, a P/E ratio of -81.24 and a beta of 0.83. The firm has a 50 day simple moving average of $124.26 and a 200 day simple moving average of $129.25. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $196.26.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Sell-side analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the stock in a transaction on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, with a total value of $151,704.00. Following the acquisition, the director owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Vivek Jain bought 21,929 shares of the stock in a transaction on Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer directly owned 130,149 shares in the company, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Saturday. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. Raymond James Financial cut their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a research note on Friday, August 8th. KeyCorp cut their target price on shares of ICU Medical from $191.00 to $173.00 and set an “overweight” rating for the company in a research note on Tuesday, October 21st. Finally, Piper Sandler lifted their target price on shares of ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $176.50.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.